Wealthfront Advisers
BBH icon

Wealthfront Advisers’s VanEck Biotech ETF BBH Stock Holding History

Wealthfront Advisers’s Portfolio BBH Stock Details BBH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.22M Sell
5,984
-1,020
-15% -$192K ﹤0.01% 694
2026
Q1 		$1.32M Buy
7,004
+1,491
+27% +$287K ﹤0.01% 670
2025
Q4 		$1.04M Buy
5,513
+122
+2% +$22.6K ﹤0.01% 705
2025
Q3 		$893K Sell
5,391
-554
-9% -$90.3K ﹤0.01% 716
2025
Q2 		$911K Sell
5,945
-1,307
-18% -$195K ﹤0.01% 696
2025
Q1 		$1.14M Buy
7,252
+1,455
+25% +$236K ﹤0.01% 635
2024
Q4 		$910K Buy
5,797
+1,261
+28% +$212K ﹤0.01% 681
2024
Q3 		$805K Buy
4,536
+50
+1% +$8.87K ﹤0.01% 688
2024
Q2 		$755K Buy
4,486
+1,021
+29% +$167K ﹤0.01% 674
2024
Q1 		$576K Buy
3,465
+526
+18% +$87.1K ﹤0.01% 713
2023
Q4 		$486K Sell
2,939
-2,290
-44% -$352K ﹤0.01% 726
2023
Q3 		$814K Buy
5,229
+1,292
+33% +$206K ﹤0.01% 599
2023
Q2 		$614K Buy
3,937
+1,549
+65% +$247K ﹤0.01% 646
2023
Q1 		$387K Buy
2,388
+14
+0.6% +$2.27K ﹤0.01% 712
2022
Q4 		$379K Buy
2,374
+357
+18% +$56.5K ﹤0.01% 680
2022
Q3 		$284K Buy
2,017
+176
+10% +$26.6K ﹤0.01% 698
2022
Q2 		$268K Sell
1,841
-59
-3% -$8.79K ﹤0.01% 706
2022
Q1 		$308K Buy
1,900
+1
+0.1% +$162 ﹤0.01% 704
2021
Q4 		$360K Sell
1,899
-340
-15% -$65.6K ﹤0.01% 647
2021
Q3 		$452K Buy
+2,239
New +$470K ﹤0.01% 574

Other funds holding BBH

Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
MIM
Miller Investment Management West Conshohocken, Pennsylvania $1.09B AUM 18.31% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
CCA
Conservest Capital Advisors Wynnewood, Pennsylvania $1.26B AUM 24.75% 1-Year Est. Return
BFG
Bleakley Financial Group Fairfield, New Jersey $7.85B AUM 31.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Wealthfront Advisers's BBH Position: Q2 2026 in Review

Wealthfront Advisers reduced its VanEck Biotech ETF (BBH) stake by 15% in Q2 2026, selling an estimated $192K and leaving 5,984 shares worth $1.22M. The position accounts for ﹤0.01% of the portfolio, ranked #694.

Wealthfront Advisers first reported a position in BBH in Q3 2021 and has held it in 20 quarters since. The position peaked at $1.32M in Q1 2026. 110 funds tracked by Wall St. Rank hold BBH as of Q2 2026.

  • Wealthfront Advisers held 5,984 shares of VanEck Biotech ETF worth $1.22M as of Q2 2026.
  • Wealthfront Advisers sold 1,020 VanEck Biotech ETF shares in Q2 2026, an estimated $192K.
  • VanEck Biotech ETF made up ﹤0.01% of Wealthfront Advisers's portfolio in Q2 2026, its #694 holding.
  • Wealthfront Advisers first reported a position in VanEck Biotech ETF in Q3 2021 and has held it in 20 quarters since.
  • Wealthfront Advisers's VanEck Biotech ETF position peaked at $1.32M in Q1 2026.
  • 110 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q2 2026.

Based on Wealthfront Advisers's 13F filing for Q2 2026, filed 7 Aug 2026.